Pancreatic Cancer Research

ResearcherErasmus MCActive in the last 2 years

Marjolein Y.V. Homs

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9828-2541; OpenAlex author ID A5078260564, A5109859706, A5121023248, A5136693625, A5153471209. Sources: ClinicalTrials.gov.

Their work

Papers
62 (first author 1, last author 0)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
160
Papers, trials and grants by year

2019: 1 paper · 2020: 7 papers · 2021: 8 papers · 2022: 7 papers · 2023: 7 papers · 2024: 5 papers, 1 trial · 2025: 12 papers · 2026: 15 papers

Papers 50 of 62

  1. Prevention of Venous Thromboembolism in Patients With Pancreatic Cancer: A Nationwide Survey. Co-author DOI 10.1002/cam4.72306↗
  2. The value of FOLFIRINOX in advanced pancreatic cancer: balancing efficacy, toxicity, and quality of life. Co-author DOI 10.1007/s00520-026-10568-3↗
  3. Comparing short- and long-term survivors in metastatic pancreatic cancer: Insights into patient and disease profiles impacting systemic therapy outcomes. Co-author DOI 10.1016/j.ejca.2026.116263↗
  4. The impact of age on quality of life, 90-day mortality, adjuvant chemotherapy, and survival after treatment for localized pancreatic cancer: A nationwide analy… Co-author DOI 10.1016/j.ejca.2026.116822↗
  5. Treatment considerations in patients with metastatic pancreatic cancer who did not receive systemic therapy: A population-based study. Co-author DOI 10.1016/j.ejca.2026.116943↗
  6. Survival benefit of recurrence-focused treatment after surgery for pancreatic ductal adenocarcinoma: A propensity score matched analysis of patients from a Dut… Co-author DOI 10.1016/j.ejca.2026.117776↗
  7. Preference versus protocol: oncology clinicians' perspectives on central venous access for administration of chemotherapy in pancreatic cancer. Co-author DOI 10.1016/j.esmogo.2026.100311↗
  8. Regional variation for tumour-directed treatment and survival in patients with pancreatic adenocarcinoma: a nationwide population-based analysis. Co-author DOI 10.1016/j.hpb.2025.12.035↗
  9. The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer - Authors' reply. Co-author DOI 10.1016/s1470-2045(25)00729-6↗
  10. Continuity of care experienced by patients diagnosed with pancreatic cancer: nationwide multicentre study. Co-author DOI 10.1093/bjsopen/zrag033↗
  11. Real-world implementation of a decision aid for treatment decisions in metastatic pancreatic cancer: a prospective multicenter study across expert centers. Co-author DOI 10.1093/oncolo/oyag373↗
  12. Pain prevalence and intensity in advanced pancreatic cancer: a nationwide cohort study. Co-author DOI 10.1097/j.pain.0000000000004059↗
  13. Staging Laparoscopy After Neoadjuvant Treatment for Pancreatic Cancer to Prevent Non-Therapeutic Laparotomy: Analysis in the PREOPANC-2 Randomized Trial. Co-author DOI 10.1097/sla.0000000000007025↗
  14. Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial. Co-author DOI 10.1200/jco-25-01935↗
  15. The Value of Stereotactic Radiotherapy After FOLFIRINOX in Patients with Pancreatic Cancer with Vascular Contact-A Nationwide, Retrospective Cohort Study. Co-author DOI 10.3390/cancers18040700↗
  16. Longitudinal health-related quality of life in patients with pancreatic cancer stratified by treatment: a nationwide cohort study. Co-author DOI 10.1016/j.eclinm.2024.103068↗
  17. Clinical relevance of next-generation sequencing in patients aged 60 years or younger with pancreatic cancer: A Nationwide prospective cohort study. Co-author DOI 10.1016/j.ejca.2025.116065↗
  18. 10-year survival after resection of pancreatic ductal adenocarcinoma with pathological re-examination of a nationwide cohort. Co-author DOI 10.1016/j.ejca.2025.116099↗
  19. KRAS mutation status integrated with RNA subtyping improves prognostic modeling in FOLFIRINOX-treated metastatic pancreatic cancer. Co-author DOI 10.1016/j.medj.2025.100601↗
  20. Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multice… Co-author DOI 10.1016/s1470-2045(25)00363-8↗
  21. REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in metastatic pancreatic cancer. Co-author DOI 10.1038/s41467-025-66092-1↗
  22. Resectability stages of pancreatic cancer: nationwide reference. Co-author DOI 10.1093/bjs/znaf120↗
  23. Delayed gastric emptying after pancreatic cancer surgery impacts time to start of adjuvant treatment but not overall survival: a post-hoc analysis of the PREOP… Co-author DOI 10.1093/bjs/znaf261↗
  24. Surgical Complications in Patients with (borderline) Resectable Pancreatic Cancer after Neoadjuvant Therapy in the PREOPANC-2 Randomized Controlled Trial. Co-author DOI 10.1097/sla.0000000000006910↗
  25. Nationwide implementation of the international multidisciplinary best-practice for locally advanced pancreatic cancer (PREOPANC-4): study protocol. Co-author DOI 10.1186/s12885-025-13554-w↗
  26. Patient preferences for pancreatic cancer treatment (PERSEUS): a multicenter discrete choice experiment. Co-author DOI 10.1186/s12955-025-02440-5↗
  27. Quality of Life Among Patients With Locally Advanced Pancreatic Cancer: A Prospective Nationwide Multicenter Study. Co-author DOI 10.6004/jnccn.2024.7091↗
  28. Implementation of Best Practices in Pancreatic Cancer Care in the Netherlands: A Stepped-Wedge Randomized Clinical Trial. Co-author DOI 10.1001/jamasurg.2023.7872↗
  29. Chemotherapy switch for localized pancreatic cancer: a systematic review and meta-analysis. Co-author DOI 10.1093/bjs/znae244↗
  30. Multidisciplinary Standards and Evolving Therapies for Patients With Pancreatic Cancer. Co-author DOI 10.1200/edbk_438598↗
  31. Nationwide Use and Outcome of Surgery for Locally Advanced Pancreatic Cancer Following Induction Chemotherapy. Co-author DOI 10.1245/s10434-023-14650-6↗
  32. ASO Author Reflections: Nationwide Experience on Locally Advanced Pancreatic Cancer Surgery After Induction Chemotherapy in the Netherlands: A Stepping Stone f… Co-author DOI 10.1245/s10434-023-14704-9↗
  33. A multigene circulating biomarker to predict the lack of FOLFIRINOX response after a single cycle in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejca.2022.12.024↗
  34. Diagnostic performance of endoscopic tissue acquisition for pancreatic ductal adenocarcinoma in the PREOPANC and PREOPANC-2 trials. Co-author DOI 10.1016/j.hpb.2023.04.018↗
  35. Feasibility, safety, and efficacy of stereotactic body radiotherapy combined with intradermal heat-killed mycobacterium obuense (IMM-101) vaccination for non-p… Co-author DOI 10.1016/j.radonc.2023.109541↗
  36. Timing of start of systemic treatment in patients with asymptomatic metastasized pancreatic cancer (TIMEPAN): a protocol of a multicenter prospective patient p… Co-author DOI 10.1080/0284186x.2023.2273898↗
  37. Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderl… Co-author DOI 10.1093/bjs/znad210↗
  38. Increasing Systemic Immune-inflammation Index During Treatment in Patients With Advanced Pancreatic Cancer is Associated With Poor Survival: A Retrospective, M… Co-author DOI 10.1097/sla.0000000000005865↗
  39. Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial. Co-author DOI 10.1186/s12885-023-11141-5↗
  40. Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.33916↗
  41. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials. Co-author DOI 10.1016/j.ejca.2021.10.023↗
  42. Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastat… Co-author DOI 10.1136/bmjopen-2021-060431↗
  43. Treatment Response and Conditional Survival in Advanced Pancreatic Cancer Patients Treated with FOLFIRINOX: A Multicenter Cohort Study. Co-author DOI 10.1155/2022/8549487↗
  44. Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREO… Co-author DOI 10.1200/jco.21.02233↗
  45. Serum cytokine levels are associated with tumor progression during FOLFIRINOX chemotherapy and overall survival in pancreatic cancer patients. Co-author DOI 10.3389/fimmu.2022.898498↗
  46. Sex, Gender and Age Differences in Treatment Allocation and Survival of Patients With Metastatic Pancreatic Cancer: A Nationwide Study. Co-author DOI 10.3389/fonc.2022.839779↗
  47. The bigger picture of shared decision making: A service design perspective using the care path of locally advanced pancreatic cancer as a case. Co-author DOI 10.1002/cam4.4145↗
  48. Readily available biomarkers predict poor survival in metastatic pancreatic cancer. Co-author DOI 10.1080/1354750x.2021.1893814↗
  49. Circulating TP53 mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX. Co-author DOI 10.1177/17588359211033704↗
  50. Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreati… Co-author DOI 10.1186/s12885-021-08031-z↗

Trials 1

  1. Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Th… Principal investigator NCT05927142↗

Closest collaborators

The 25 strongest of 160 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Johanna W. Wilmink · 45 shared papers, 2019–2026 · strength 7.44
  2. Marc G. Besselink · 40 shared papers, 2019–2026 · strength 6.26
  3. Casper H.J. van Eijck · 36 shared papers, 1 shared trial, 2019–2026 · strength 5.93
  4. Judith de Vos‐Geelen · 34 shared papers, 2020–2026 · strength 5.91
  5. Bas Groot Koerkamp · 35 shared papers, 2019–2026 · strength 5.28
  6. Ignace H. J. T. de Hingh · 25 shared papers, 2020–2026 · strength 4.13
  7. Bert A. Bonsing · 24 shared papers, 2020–2026 · strength 3.61
  8. Hjalmar C. van Santvoort · 20 shared papers, 2020–2026 · strength 3.33
  9. Hanneke W.M. van Laarhoven · 19 shared papers, 2020–2026 · strength 3.09
  10. Lydia G. van der Geest · 15 shared papers, 2020–2026 · strength 2.50
  11. Vincent Erwin de Meijer · 11 shared papers, 2020–2026 · strength 2.00
  12. Geertjan van Tienhoven · 14 shared papers, 2019–2026 · strength 1.99
  13. Izaak Quintus Molenaar · 13 shared papers, 2020–2026 · strength 1.96
  14. Quisette P. Janssen · 13 shared papers, 2019–2026 · strength 1.89
  15. Martijn W.J. Stommel · 11 shared papers, 2020–2026 · strength 1.83
  16. Jacob L. van Dam · 11 shared papers, 2021–2026 · strength 1.73
  17. Jeanin Elise van Hooft · 10 shared papers, 2020–2026 · strength 1.60
  18. Merlijn U.J.E. Graus · 6 shared papers, 2026 · strength 1.44
  19. Brigitte C.M. Haberkorn · 9 shared papers, 2021–2026 · strength 1.44
  20. Lois A. Daamen · 7 shared papers, 2023–2026 · strength 1.34
  21. Simone Augustinus · 6 shared papers, 2023–2026 · strength 1.25
  22. Aniek E. van Diepen · 5 shared papers, 2025–2026 · strength 1.24
  23. Roeland F. de Wilde · 7 shared papers, 2021–2026 · strength 1.19
  24. Stefan A.W. Bouwense · 6 shared papers, 2022–2026 · strength 1.11
  25. Thijmen H.T. Broekman · 5 shared papers, 2023–2026 · strength 1.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.